Wall Street analyst estimates for Vera Therapeutics, Inc. (VERA): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $23.1M | $20.1M – $30.9M | -$6.25 | 9 |
| 2027E | $230M | $160M – $365M | -$4.27 | 9 |
| 2028E | $599M | $268M – $919M | -$0.59 | 10 |
Figures in USD · consensus as of November 3, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 12 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.62 | ||
| 2026-08-10 | $-1.52 | $-1.58 | +3.8% |
| 2026-05-07 | $-1.69 | $-1.33 | -27.2% |
| 2026-02-26 | $-1.39 | $-1.34 | -3.7% |
| 2025-11-05 | $-1.26 | $-1.20 | -5.0% |
| 2025-08-05 | $-1.20 | $-0.82 | -46.3% |
| 2025-05-06 | $-0.81 | $-0.75 | -8.0% |
| 2025-02-26 | $-0.72 | $-0.83 | +13.3% |
Valuation Ratios
| Price / Book | 5.63 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $509,000 | $251,000 | 0 | -$846,000 | 0 | 0 | 0 |
| Gross Profit | -$509,000 | -$251,000 | 0 | $846,000 | 0 | 0 | 0 |
| Research & Development | $7.3M | $43.9M | $22.5M | $69.8M | $78.2M | $126.2M | $215.3M |
| Selling, General & Admin | $4.4M | $3.9M | $11.9M | $21.9M | $23.8M | $41.0M | $100.2M |
| Operating Expenses | $11.7M | $47.8M | $34.4M | $91.7M | $102.0M | $167.2M | $315.5M |
| Operating Income | -$12.0M | -$48.1M | -$34.4M | -$90.9M | -$102.0M | -$167.2M | -$315.5M |
| EBITDA | -$11.3M | -$53.0M | -$32.4M | -$88.9M | -$92.2M | -$144.4M | -$291.6M |
| Interest Expense | $51,000 | $166,000 | $20,000 | $992,000 | $3.8M | $7.6M | $7.5M |
| Pre-tax Income | -$11.9M | -$53.4M | -$32.6M | -$89.1M | -$96.0M | -$152.1M | -$299.6M |
| Income Tax | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net Income | -$11.9M | -$53.4M | -$32.6M | -$89.1M | -$96.0M | -$152.1M | -$299.6M |
| EPS | -$3.46 | -$14.40 | -$2.43 | -$3.35 | -$2.25 | -$2.75 | -$4.66 |
| EPS (Diluted) | -$3.46 | -$14.40 | -$2.43 | -$3.35 | -$2.25 | -$2.75 | -$4.66 |
| Shares Outstanding (Diluted) | 3.4 M | 3.7 M | 13.4 M | 26.6 M | 42.7 M | 55.3 M | 64.2 M |
Price
| Price | $31.97 (closing price, November 4, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Related companies: DNTH · ARQT · BHVN · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of VERA: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks